Marinus Verwijs - Jan 22, 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
CHIEF TECHNOLOGY OFFICER
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Stock symbol
AVTE
Transactions as of
Jan 22, 2024
Transactions value $
$0
Form type
4
Date filed
1/24/2024, 06:00 PM
Previous filing
Nov 3, 2023
Next filing
Mar 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +66.6K $0.00 66.6K Jan 22, 2024 Common Stock 66.6K $20.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.